EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% [2]

Basit Öğe Kaydı
dc.authorid0000-0002-8417-8628
dc.authorid0000-0002-6445-1439
dc.contributor.authorSezer, A.
dc.contributor.authorKılıçkap, S.
dc.contributor.authorGümüş, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorTurk, H. M.
dc.date.accessioned2025-05-10T19:48:31Z
dc.date.issued2020
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionESMO Virtual Congress -- SEP 19-OCT 18, 2020 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipEuropean Soc Med Oncol
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.; Sanofi
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc. and Sanofi.
dc.identifier.doi10.1016/j.annonc.2020.08.2285
dc.identifier.endpageS1183
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.scopusqualityQ1
dc.identifier.startpageS1182
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2020.08.2285
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11728
dc.identifier.volume31
dc.identifier.wosWOS:000573469102683
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.titleEMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% [2]
dc.typeConference Object

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11728.pdf
Boyut:
106.37 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu